drugset
drugset / Trial / NCT01404936

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

NCT01404936 ↗

Phase 2 Completed 35 enrolled M.D. Anderson Cancer Center Schering-Plough · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a clinical research study of interferon (IFN) plus chemotherapy with the standard combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be given to patients with Hodgkin's disease. The study will look at whether adding IFN to ABVD improves the immune response against Hodgkin's disease, and will determine whether the toxicity of ABVD is increased by adding IFN.

Timeline

Start
1996-07
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject interferon alfa Protein / enzyme biologic 4e+06 iu Subcutaneous
Background Bleomycin Unknown 10 mg/m2 Intravenous
Background Dacarbazine Small molecule 375 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Background Vinblastine Small molecule 6 mg/m2 Intravenous

Indications

lymphoma